Inclusion complexes of atorvastatin calcium (ATV-Ca) and rosuvastatin calcium (ROV-Ca) drugs with α-CD, β-CD, γ-CD, HP-β-CD, M-β-CD, and maltodextrin along with their characterizations through experimental and computational methods

The aim of this research is a comparison of the efficiency of six commercially available cyclodextrins (CDs) to improve the solubility and oral bioavailability of atorvastatin calcium (ATV-Ca) and rosuvastatin calcium (ROV-Ca) drugs in aqueous media. Inclusion complexes of both drugs with non-toxic α-CD, β-CD, γ-CD, HP-β-CD, M-β-CD, and maltodextrin were prepared in a 1:1 stoichiometry via the kneading method. To reach the best CD, various experimental and computational analyses were performed including phase solubility, dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), atomic force microscopy (AFM), hydrogen-1 nuclear magnetic resonance (¹HNMR), carbon-13 nuclear magnetic resonance (¹³CNMR), and molecular docking calculations. The M-β-CD turned out to be the best substrate for the micro-encapsulation of both drugs. Also, ATV showed a higher tendency than ROV to form inclusion complexes with CDs. Molecular docking studies showed that HP–β–CD and M-β-CD are the most suitable substrates for the formation of inclusion complexes, respectively. Our research showed that the β-CD is not necessarily the most efficient substrate for increasing solubility based on previous reports in the literature; meanwhile, the other employed substrates in this study can show acceptable performances in this regard. According to our results, M-β-CD is the best substrate for the micro-encapsulation of both drugs, which increases their solubility in water. (author)